[6-K] KAZIA THERAPEUTICS LTD Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Kazia Therapeutics Limited reports that it has not regained compliance with Nasdaq’s minimum Market Value of Listed Securities requirement of $35 million under Listing Rule 5550(b)(2) by the November 10, 2025 compliance date. Nasdaq staff sent a determination letter on November 12, 2025 stating that, absent further action, the company’s securities would be subject to suspension or delisting from The Nasdaq Capital Market.

Kazia intends to timely request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action while the hearing process and any granted extension period are pending. The company plans to present a case that it can regain compliance and maintain it over the long term, but cautions that there is no assurance the Panel will accept its plan or that compliance will ultimately be restored.

Positive

• None.

Negative

• Kazia did not regain compliance with Nasdaq’s $35 million Market Value of Listed Securities requirement by the November 10, 2025 deadline, triggering a staff determination that its securities are subject to suspension or delisting.
• Nasdaq listing status is uncertain because the outcome of the upcoming Hearings Panel review is not assured, and the company warns there is no guarantee it will ultimately regain or maintain compliance.

Insights

Equity market structure analyst

Kazia faces Nasdaq delisting risk after missing the MVLS compliance deadline.

Kazia Therapeutics confirms that its Market Value of Listed Securities stayed below the $35 million minimum required by Nasdaq Listing Rule 5550(b)(2) between March 28 and May 9, 2025, and that it did not regain compliance by the November 10, 2025 deadline. Nasdaq staff issued a determination letter on November 12, 2025 stating the company’s securities are subject to suspension or delisting from The Nasdaq Capital Market.

The company plans to request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting action during the hearing process and any extension period granted by the Panel. At that hearing, Kazia intends to demonstrate how it can regain and sustain compliance with all listing criteria, including the MVLS requirement.

The company explicitly notes that there can be no assurance the Panel will accept its plan or that compliance will be regained. This introduces ongoing listing uncertainty until the hearing is completed and a decision is reached, with the ultimate outcome dependent on the Panel’s review and Kazia’s ability to meet Nasdaq’s continued listing standards.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2025

Commission File Number 000-29962

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

As previously disclosed, Kazia Therapeutics Limited (the “Company”) received a notice (the “Notice”) from the Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on May 12, 2025 notifying the Company that from March 28, 2025 to May 9, 2025, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with 180 calendar days, or until November 10, 2025 (the “Compliance Date”), to regain compliance with the MVLS Requirement.

On November 12, 2025, the Company received a staff determination letter (“Staff Letter”) from the Staff of Nasdaq indicating that the Company had not regained compliance with the MVLS Requirement by November 10, 2025. Pursuant to the Nasdaq Listing Rules and the Staff Letter, unless the Company timely requests a hearing before a Hearings Panel (the “Panel”), the Company’s securities would be subject to suspension/delisting. Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing.

At the hearing, the Company intends to demonstrate its ability to regain compliance with the deficiencies cited by the Staff, as well as its ability to sustain long-term compliance with all applicable maintenance criteria. There can be no assurance that the Company’s plan to regain compliance presented at the hearing will be accepted by the Panel, or that, if it is, the Company will be able to regain compliance with the applicable Nasdaq listing requirements.

The Company hereby incorporates by reference the information contained herein into the Company’s registration statement on Form F-3 (File No. 333-281937).

Forward-Looking Statements

This report of foreign private issuer on Form 6-K may contain forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” or other similar words. Any statement describing Kazia’s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, statements regarding: Kazia’s intent to demonstrate its ability to regain compliance with the MVLS requirement, the outcome of the Panet’s review of any Kazia appeal of the Staff’s determination, and any course of action to regain compliance with the Nasdaq continued listing requirements. Such statements are based on Kazia’s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with Kazia’s ability to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia’s Annual Report, filed on Form 20-F with the SEC on November 7, 2025, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this report of foreign private issuer on Form 6-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant)

/s/ John Friend

John Friend

Chief Executive Officer

Date: November 18, 2025

FAQ

Why did Kazia Therapeutics (KZIA) receive a Nasdaq noncompliance notice?

Kazia Therapeutics received a Nasdaq notice because its Market Value of Listed Securities was below the required $35 million minimum under Listing Rule 5550(b)(2) from March 28, 2025 to May 9, 2025.

What did Nasdaq communicate to Kazia Therapeutics (KZIA) on November 12, 2025?

On November 12, 2025, Nasdaq staff sent a determination letter stating that because Kazia had not regained compliance with the MVLS requirement by November 10, 2025, its securities would be subject to suspension or delisting unless it requests a hearing.

How is Kazia Therapeutics (KZIA) responding to the Nasdaq delisting risk?

Kazia intends to timely request a hearing before a Nasdaq Hearings Panel. That request will automatically stay any suspension or delisting action during the hearing and any extension period granted by the Panel.

Does requesting a Nasdaq hearing guarantee Kazia Therapeutics (KZIA) will remain listed?

No. While the hearing request stays any immediate suspension or delisting, Kazia states there is no assurance its compliance plan will be accepted or that it will ultimately regain and maintain compliance with Nasdaq listing requirements.

What specific Nasdaq requirement is Kazia Therapeutics (KZIA) trying to satisfy?

Kazia is addressing Nasdaq Listing Rule 5550(b)(2), which requires a minimum Market Value of Listed Securities of $35 million for continued listing on The Nasdaq Capital Market.

How does this Nasdaq issue relate to Kazia Therapeutics (KZIA) SEC filings?

Kazia incorporates this information by reference into its Form F-3 registration statement (File No. 333-281937), linking the listing status update to its existing SEC registration.